Results 91 to 100 of about 854 (146)

CEP889350 Supplemetal Material7 - Supplemental material for Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans

, 2019
Supplemental material, CEP889350 Supplemetal Material7 for Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans by Kerry Knievel, Andrew S Buchanan, Louise Lombard, Simin Baygani, Joel Raskin, John H Krege, Li ...
Li Shen Loo (7905155), Louise Lombard (6813860), Mika Komori (114112), Andrew S Buchanan (7905152), John H Krege (7875398), Joel Raskin (7875404), Kerry Knievel (7905149), Joshua Tobin (7905158), Simin Baygani (7039025)   +8 more
core   +1 more source

CEP889350 Supplemetal Material9 - Supplemental material for Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans

, 2019
Supplemental material, CEP889350 Supplemetal Material9 for Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans by Kerry Knievel, Andrew S Buchanan, Louise Lombard, Simin Baygani, Joel Raskin, John H Krege, Li ...
Li Shen Loo (7905155), Louise Lombard (6813860), Mika Komori (114112), Andrew S Buchanan (7905152), John H Krege (7875398), Joel Raskin (7875404), Kerry Knievel (7905149), Joshua Tobin (7905158), Simin Baygani (7039025)   +8 more
core   +1 more source

CEP889350 Supplemetal Material2 - Supplemental material for Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans

, 2019
Supplemental material, CEP889350 Supplemetal Material2 for Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans by Kerry Knievel, Andrew S Buchanan, Louise Lombard, Simin Baygani, Joel Raskin, John H Krege, Li ...
Li Shen Loo (7905155), Louise Lombard (6813860), Mika Komori (114112), Andrew S Buchanan (7905152), John H Krege (7875398), Joel Raskin (7875404), Kerry Knievel (7905149), Joshua Tobin (7905158), Simin Baygani (7039025)   +8 more
core   +1 more source

Determining the Advantageous Acute Migraine Treatment: Rimegepant and Lasmiditan Review of Literature [PDF]

, 2020
This research aims to evaluate two new pharmaceuticals on the market. Rimegepant and Lasmiditan target the trigeminovascular system and respectively, are characterized in the gepant and ditan classes of pharmaceuticals.
Johnson, Tiffany A
core  

CEP889350 Supplemetal Material3 - Supplemental material for Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans

, 2019
Supplemental material, CEP889350 Supplemetal Material3 for Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans by Kerry Knievel, Andrew S Buchanan, Louise Lombard, Simin Baygani, Joel Raskin, John H Krege, Li ...
Li Shen Loo (7905155), Louise Lombard (6813860), Mika Komori (114112), Andrew S Buchanan (7905152), John H Krege (7875398), Joel Raskin (7875404), Kerry Knievel (7905149), Joshua Tobin (7905158), Simin Baygani (7039025)   +8 more
core   +1 more source

CEP889350 Supplemetal Material4 - Supplemental material for Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans

, 2019
Supplemental material, CEP889350 Supplemetal Material4 for Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans by Kerry Knievel, Andrew S Buchanan, Louise Lombard, Simin Baygani, Joel Raskin, John H Krege, Li ...
Li Shen Loo (7905155), Louise Lombard (6813860), Mika Komori (114112), Andrew S Buchanan (7905152), John H Krege (7875398), Joel Raskin (7875404), Kerry Knievel (7905149), Joshua Tobin (7905158), Simin Baygani (7039025)   +8 more
core   +1 more source

Lasmiditan as a potential targeted therapy for vestibular migraine? A case study

Cephalalgia Reports
Background Vestibular migraine (VM) is a common migraine subtype. Treatment options in the acute stage are limited. Case Here, we present the case of a 53-year-old woman experiencing frequent episodes of sensory aura, as well as vertigo and right-sided ...
Patrik Theodor Nerdal, Soenke Peters, Walter Maetzler   +2 more
doaj   +1 more source

Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential

Journal of Pain Research, 2018
Andrea Negro,1,2 Angela Koverech,2,3 Paolo Martelletti1,2 1Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy; 2Department of Internal and Emergency Medicine, Regional Referral Headache Centre, Sant’Andrea Hospital ...
Negro A, Koverech A, Martelletti P
doaj  

Pharmacological Management of Acute Migraine: A Systematic Review Comparing NSAIDs, Triptans, Gepants, and Opioids

Journal of Education, Health and Sport
Background. Migraine is a complex neurobiological disorder associated with the activation of the trigeminovascular system. Many new publications about new drugs appear, but not all of them assign the drug to the most appropriate group of patients ...
Wiktor Kowalczyk, Weronika Olech, Julia Kępska, Aneta Synakiewicz, Natalia Lewińska, Aleksandra Pociej, Arina Drobashko, Nikola Murawska, Kamil Wójcik, Nicole Bulińska   +9 more
doaj   +1 more source

Editorial: Novel migraine therapies: consolidating evidence from the real world

Frontiers in Pain Research, 2023
Lanfranco Pellesi
doaj   +1 more source